Clinical trial
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related…
NCT02686658 · IVERIC bio, Inc., Industry · Completed
Key facts
| NCT number | NCT02686658 |
|---|---|
| Title | Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration |
| Official title | A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration |
| Lead sponsor | IVERIC bio, Inc., Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Geographic Atrophy, Dry Age-Related Macular Degeneration |
| Intervention type | Drug, Other |
| Interventions | Avacincaptad Pegol, Sham |
| Enrollment | 286 |
| Start date | Dec 15, 2015 |
| Primary completion | Sep 26, 2019 |
| Completion | Apr 23, 2020 |
| First posted | Feb 19, 2016 |
| Last update posted | Jun 10, 2025 |
| Countries | Croatia, Czechia, Estonia, Hungary, Israel, Latvia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: